The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Cognitive decline in Parkinson disease
Open accessAbstract
Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD). In recent years, research has focused on the pre-dementia stages of cognitive impairment in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of cognition - or even reversal to normal cognition - is not uncommon. In addition to limbic and cortical spread of Lewy pathology, several other mechanisms are likely to contribute to cognitive decline in PD, and a variety of biomarker studies, some using novel structural and functional imaging techniques, have documented in vivo brain changes associated with cognitive impairment. The evidence consistently suggests that low cerebrospinal fluid levels of amyloid-β 42, a marker of comorbid Alzheimer disease (AD), predict future cognitive decline and dementia in PD. Emerging genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Cognitive enhancing medications have some effect in PD dementia, but no convincing evidence that progression from MCI to dementia can be delayed or prevented is available, although cognitive training has shown promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationLitvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Self-citationThe Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,346
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Self-citationMultimodal classification of Alzheimer's disease and mild cognitive impairment
Zhang, D., Wang, Y., Zhou, L., Yuan, H., & Shen, D. G. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.008 · Cited by 1,340
Cited by
Sorted by citations
Items 101–200 of 1,000
da Conceição, N. R., Gobbi, L. T. B., Nóbrega‐Sousa, P., Orcioli‐Silva, D., Beretta, V. S., Lirani‐Silva, E., Okano, A. H., & Vitório, R. R. (2021) · Neurorehabilitation and neural repair · doi:10.1177/15459683211019344 · Cited by 61
Liu, T., Zuo, H., Ma, D., Song, D., Zhao, Y., & Cheng, O. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02843-5 · Cited by 59
Leta, V., Urso, D., Batzu, L., Weintraub, D., Titova, N., Aarsland, D., Martinez-Martin, P., Borghammer, P., van Wamelen, D. J., Yousaf, T., et al. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212570 · Cited by 58
Self-citationFarì, G., Lunetti, P., Pignatelli, G., Raele, M. V., Cera, A., Mintrone, G., Ranieri, M., Megna, M., & Capobianco, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111632 · Cited by 64
Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease
Williams, G. P., Schonhoff, A. M., Sette, A., & Arlehamn, C. S. L. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223241 · Cited by 61
The Gut Microbiome–Brain Crosstalk in Neurodegenerative Diseases
Ghezzi, L., Cantoni, C., Rotondo, E., & Galimberti, D. (2022) · Biomedicines · doi:10.3390/biomedicines10071486 · Cited by 61
Mind the gaps: What we don't know about cognitive impairment in essential tremor
Louis, E. D., Joyce, J. L., & Cosentino, S. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.02.038 · Cited by 58
Chung, S. J., Yoo, H. S., Lee, Y. H., Lee, H. S., Ye, B. S., Sohn, Y. H., Kwon, H., & Lee, P. H. (2019) · Human Brain Mapping · doi:10.1002/hbm.24631 · Cited by 56
Dementia in long-term Parkinson’s disease patients: a multicentre retrospective study
Szeto, J. Y. Y., Walton, C. C., Rizos, A., Martínez‐Martín, P., Halliday, G. M., Naismith, S. L., Chaudhuri, К. R., & Lewis, S. J. G. (2020) · npj Parkinson s Disease · doi:10.1038/s41531-019-0106-4 · Cited by 57
Taddei, R. N., Çankaya, Ş., Dhaliwal, S., & Chaudhuri, К. R. (2017) · Parkinson s Disease · doi:10.1155/2017/3256542 · Cited by 55
Espay, A. J., Guskey, M. T., Norton, J. C., Coate, B., Vizcarra, J. A., Ballard, C. G., Factor, S. A., Friedman, J. H., Lang, A. E., Larsen, N. J., et al. (2018) · Movement Disorders · doi:10.1002/mds.27488 · Cited by 56
Self-citationGut, oral and nasal microbiota and Parkinson’s disease
Shen, L. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01313-4 · Cited by 58
Shin, N., Bang, M., Yoo, S., Kim, J., Yun, E., Yoon, U., Han, K., Ahn, K. J., & Lee, S. (2021) · Radiology · doi:10.1148/radiol.2021203383 · Cited by 55
Sharma, N., Soni, R., Sharma, M., Chatterjee, S., Parihar, N., Mukarram, M., kale, R., Sayyed, A. A., Behera, S. K., & Khairnar, A. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03005-z · Cited by 54
Identification of potential diagnostic biomarkers for Parkinson's disease
Jiang, F., Wu, Q., Sun, S., Bi, G., & Guo, L. T. (2019) · FEBS Open Bio · doi:10.1002/2211-5463.12687 · Cited by 53
Almgren, H., Camacho, M., Hanganu, A., Kibreab, M., Camicioli, R. M., Ismail, Z., Forkert, N. D., & Monchi, O. (2023) · Scientific Reports · doi:10.1038/s41598-023-37644-6 · Cited by 52
Jakaria, M., Haque, M. E., Kim, J.-S., Cho, D.-Y., Kim, I., & Choi, D. (2018) · Oncotarget · doi:10.18632/oncotarget.26035 · Cited by 52
Schreiner, S. J., Imbach, L., Valko, P. O., Maric, A., Maqkaj, R., Werth, E., Baumann, C. R., & Baumann‐Vogel, H. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.618101 · Cited by 56
Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson’s Disease
Ma, L., Zhang, C. M., Wang, H., Ma, Y., Shen, X., Wang, J., Tan, L., Dong, Q., & Yu, J. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212535 · Cited by 51
Biomarkers for cognitive dysfunction in Parkinson's disease
Kalia, L. V. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.07.023 · Cited by 49
White Matter Hyperintensities Related to Parkinson's Disease Executive Function
Linortner, P., McDaniel, C., Shahid, M., Levine, T. F., Tian, L., Cholerton, B., & Poston, K. L. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12956 · Cited by 49
Imaging Mild Cognitive Impairment and Dementia in Parkinson's Disease
Sasikumar, S., & Strafella, A. P. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00047 · Cited by 58
Fiorenzato, E., Cauzzo, S., Weis, L., Garon, M., Pistonesi, F., Cianci, V., Nasi, M. L., Vianello, F., Zecchinelli, A., Pezzoli, G., et al. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123283 · Cited by 50
Stokholm, M. G., Iranzo, Á., Østergaard, K., Serradell, M., Otto, M., Svendsen, K. B., Garrido, A., Vilas, D., Parbo, P., Borghammer, P., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.02.017 · Cited by 49
Li, D. T. H., Hui, E. S. K., Chan, Q., Yao, N., Chua, S. E., McAlonan, G. M., Pang, S. Y.-Y., Ho, S. L., & Mak, H. K. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.07.028 · Cited by 50
Gour, N., Kshtriya, V., Gupta, S., Koshti, B., Singh, R. S., Patel, D., & Joshi, K. B. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00627 · Cited by 49
Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?
Biundo, R., Weis, L., Fiorenzato, E., & Antonini, A. (2017) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx092 · Cited by 49
Chaturvedi, M., Bogaarts, J. G., Kozak, V. V., Hatz, F., Gschwandtner, U., Meyer, A., Fuhr, P., & Röth, V. (2019) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.07.017 · Cited by 49
Liu, L., Li, M., Xu, M., Wang, Z., Zeng, Z., Li, Y.-Q., Zhang, Y., You, R., Li, C., & Guan, Y. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111028 · Cited by 49
Dopamine D2R is Required for Hippocampal-dependent Memory and Plasticity at the CA3-CA1 Synapse
Espadas, I., Ortiz, Ó., García‐Sanz, P., Sanz‐Magro, A., Alberquilla, S., Solís, Ó., Delgado-Garcia, J. M., Gruart, A., & Moratalla, R. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa354 · Cited by 51
Pawlik, P., & Błochowiak, K. J. (2021) · Diagnostics · doi:10.3390/diagnostics11020371 · Cited by 48
Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease
Longardner, K., Bayram, E., & Litvan, I. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00897 · Cited by 48
Liu, W., Tung, T., Zhang, C., & Shi, L. (2022) · Brain and Behavior · doi:10.1002/brb3.2690 · Cited by 55
Brain–immune interaction mechanisms: Implications for cognitive dysfunction in psychiatric disorders
Zhao, F., Li, B., Yang, W., Ge, T., & Cui, R. (2022) · Cell Proliferation · doi:10.1111/cpr.13295 · Cited by 50
Nijhuis, F. A. P., van den Heuvel, L., Bloem, B. R., Post, B., & Meinders, M. J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00896 · Cited by 48
Zhang, J., Gao, Y., He, X.-T., Feng, S., Hu, J., Zhang, Q., Zhao, J., Huang, Z., Wang, L., Ma, G., et al. (2021) · European Radiology · doi:10.1007/s00330-020-07575-1 · Cited by 47
Pamphlett, R., & Bishop, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262464 · Cited by 48
Dementia spectrum disorders: lessons learnt from decades with PET research
Wilson, H., Pagano, G., & Politis, M. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01975-4 · Cited by 50
Self-citationStuckenschneider, T., Askew, C. D., Menêses, A. L., Baake, R., Weber, J., & Schneider, S. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-181484 · Cited by 48
Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders
Khan, I., Kumari, P., Fernandes, V., Khatri, D. K., & Singh, S. B. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01093-4 · Cited by 49
Roles of physical exercise in neurodegeneration: reversal of epigenetic clock
Xu, M., Zhu, J., Liu, X.-D., Luo, M.-Y., & Xu, N.-J. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00254-1 · Cited by 46
Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease
Harvey, J., Reijnders, R. A., Cavill, R., Duits, A., Köhler, S., Eijssen, L., Rutten, B. P. F., Shireby, G. L., Torkamani, A., Creese, B., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00409-5 · Cited by 50
Self-citationMekkes, N., Groot, M., Hoekstra, E., de Boer, A., Dagkesamanskaia, E., Bouwman, S., Wehrens, S. M. T., Herbert, M. K., Wever, D. D., Rozemüller, A. J. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02843-9 · Cited by 47
Psychosis in Parkinson's Disease
Ffytche, D. H., & Aarsland, D. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.04.005 · Cited by 45
Self-citationPaul, S. S., Dibble, L. E., & Peterson, D. S. (2018) · Gait & Posture · doi:10.1016/j.gaitpost.2018.01.026 · Cited by 45
Progressive brain atrophy in Parkinson's disease patients who convert to mild cognitive impairment
Zhou, C., Guan, X., Guo, T., Zeng, Q., Gao, T., Huang, P., Xuan, M., Gu, Q., Xu, X., & Zhang, M. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13188 · Cited by 45
Alrawis, M., Al-Ahmadi, S. A., & Mohammad, F. (2024) · Applied Sciences · doi:10.3390/app14093883 · Cited by 44
Use of Cholinesterase Inhibitors in Non-Alzheimer’s Dementias
Noufi, P., Khoury, R., Jeyakumar, S., & Grossberg, G. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00685-6 · Cited by 37
Structural Imaging in Parkinson’s Disease: New Developments
Prange, S., Météreau, É., & Thobois, S. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-0964-5 · Cited by 45
Parkinson disease clinical subtypes: key features & clinical milestones
Campbell, M. C., Myers, P. S., Weigand, A. J., Foster, E. R., Cairns, N. J., Jackson, J. J., Lessov‐Schlaggar, C. N., & Perlmutter, J. S. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51102 · Cited by 44
Factor analysis–derived cognitive profile predicting early dementia conversion in PD
Chung, S. J., Lee, H. S., Kim, H.-R., Yoo, H. S., Lee, Y. H., Jung, J. H., Baik, K., Ye, B. S., Sohn, Y. H., & Lee, P. H. (2020) · Neurology · doi:10.1212/wnl.0000000000010347 · Cited by 44
Limegrover, C. S., Yurko, R., Izzo, N. J., LaBarbera, K. M., Rehak, C., Look, G., Rishton, G., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24782 · Cited by 43
Luengos, I. S., Balboa-Bandeira, Y., Lucas‐Jiménez, O., Ojeda, N., Peña, J., & Ibarretxe‐Bilbao, N. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050429 · Cited by 46
Caveolin-1, a novel player in cognitive decline
Tang, W., Li, Y., Li, Y., & Wang, Q. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.044 · Cited by 43
Imaging of Substantia Nigra in Parkinson’s Disease: A Narrative Review
Feraco, P., Gagliardo, C., Tona, G. L., Bruno, E., D’Angelo, C., Marrale, M., Poggio, A. D., Malaguti, M. C., Geraci, L., Baschi, R., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11060769 · Cited by 42
Sivandzadeh, G. R., Askari, H., Safarpour, A. R., Ejtehadi, F., Raeis-Abdollahi, E., Armaghan Vaez, L. A. R. I., Abazari, M. F., Tarkesh, F., & Lankarani, K. B. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i22.6178 · Cited by 42
Shibata, H., Uchida, Y., Inui, S., Kan, H., Sakurai, K., Oishi, N., Ueki, Y., Oishi, K., & Matsukawa, N. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.12.004 · Cited by 42
Pang, H., Wang, J., Yu, Z., Hong-mei, Y., Li, X., Bu, S., Zhao, M., Jiang, Y., Liu, Y., & Fan, G. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12525-8 · Cited by 42
Network basis of the dysexecutive and posterior cortical cognitive profiles in Parkinson's disease
Lang, S., Hanganu, A., Gan, L. S., Kibreab, M., Auclair‐Ouellet, N., Alrazi, T., Ramezani, M., Cheetham, J., Hammer, T., Kathol, I., et al. (2019) · Movement Disorders · doi:10.1002/mds.27674 · Cited by 45
The BSSG rat model of Parkinson’s disease: progressing towards a valid, predictive model of disease
Kampen, J. M. V., & Robertson, H. A. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0114-6 · Cited by 43
Rotenone impairs oxidant/antioxidant balance both in brain and intestines in zebrafish
Ünal, İ., Üstündağ, Ü. V., Ateş, P. S., Eğilmezer, G., Alturfan, A. A., Yiğitbaşı, T., & Emekli‐Alturfan, E. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1538141 · Cited by 42
Jaramillo-Jiménez, A., Suárez-Revelo, J. X., Ochoa-Gómez, J. F., Arroyave, J. A. C., Bocanegra, Y., Lopera, F. J., Buriticá, O., Pineda-Salazar, D. A., Gómez, L. M., Tobón, C., et al. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.01.001 · Cited by 41
Self-citationPhysical activity profiles in Parkinson’s disease
Rosen, P., Hagströmer, M., Franzén, E., & Leavy, B. (2021) · BMC Neurology · doi:10.1186/s12883-021-02101-2 · Cited by 41
Voits, T., Pliatsikas, C., Robson, H., & Rothman, J. (2020) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2020.107593 · Cited by 40
Cascone, A., Langella, S., Sklerov, M., & Dayan, E. (2021) · Communications Biology · doi:10.1038/s42003-021-02478-3 · Cited by 40
Zhao, R., Tian, X., Xu, H., Wang, Y., Lin, J., & Wang, B. (2025) · Aging Cell · doi:10.1111/acel.70061 · Cited by 42
Training working memory updating in Parkinson’s disease: A randomised controlled trial
Fellman, D., Salmi, J., Ritakallio, L., Ellfolk, U., Rinne, J. O., & Laine, M. (2018) · Neuropsychological Rehabilitation · doi:10.1080/09602011.2018.1489860 · Cited by 40
Armstrong, M. J. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000685 · Cited by 39
Choi, J., Shin, S. J., Kim, H. J., Park, J., Kim, H. J., Lee, E. H., Pae, A. N., Bahn, Y., & Park, K. D. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00163 · Cited by 39
Plasma exosomal prion protein levels are correlated with cognitive decline in PD patients
Leng, B., Sun, H., Zhao, J., Liu, Y., Shen, T., Liu, W., Liu, X., Tan, M., Li, F., Zhang, J., et al. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134866 · Cited by 39
On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications
Inyushin, M. Y., Zayas‐Santiago, A., Rojas, L. V., & Kucheryavykh, L. Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571083 · Cited by 43
Sampedro, F., Martínez‐Horta, S., Marín‐Lahoz, J., Pagonabarraga, J., & Kulisevsky, J. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.09.031 · Cited by 37
Zarifkar, P., Kim, J., La, C., Zhang, K., YorkWilliams, S. L., Levine, T. F., Tian, L., Borghammer, P., & Poston, K. L. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.01.002 · Cited by 39
Henderson, Y. O., Bithi, N., Link, C., Yang, J., Schugar, R. C., Llarena, N. C., Brown, J. M., & Hine, C. (2021) · GeroScience · doi:10.1007/s11357-021-00330-4 · Cited by 39
Foveal Remodeling of Retinal Microvasculature in Parkinson’s Disease
Murueta‐Goyena, A., Barrenechea, M., Erramuzpe, A., Teijeira‐Portas, S., Pengo, M., Ayala, U., Romero-Bascones, D., Acera, M., Pino, R. D., Gómez‐Esteban, J. C., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708700 · Cited by 39
The toxic metal hypothesis for neurological disorders
Pamphlett, R., & Bishop, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1173779 · Cited by 44
Wilkin, K., Fang, M. L., & Sixsmith, J. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-04888-4 · Cited by 37
Bezdíček, O., Ballarini, T., Herman Buschke, L., Růžička, F., Roth, J., Albrecht, F., Růžička, E., Mueller, K., Schroeter, M. L., & Jech, R. (2019) · Neuropsychology · doi:10.1037/neu0000503 · Cited by 38
Boon, L. I., Hepp, D. H., Douw, L., van Geenen, N., Broeders, T. A. A., Geurts, J. J. G., Berendse, H. W., & Schoonheim, M. M. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102468 · Cited by 37
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
Jung, Y. J., Tweedie, D., Scerba, M. T., Kim, D. S., Palmas, M. F., Pisanu, A., Carta, A. R., & Greig, N. H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.656921 · Cited by 37
Brain functional network abnormalities in parkinson’s disease with mild cognitive impairment
Suo, X., Lei, D., Li, N., Peng, J., Chen, C., Li, W., Qin, K., Kemp, G. J., Peng, R., & Gong, Q. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhab520 · Cited by 37
Bäckström, D. C., Granåsen, G., Mo, S. J., Riklund, K., Trupp, M., Zetterberg, H., Blennow, K., Forsgren, L., & Domellöf, M. E. (2022) · Brain Communications · doi:10.1093/braincomms/fcac040 · Cited by 42
Rossetto, F., Borgnis, F., Isernia, S., Foglia, E., Garagiola, E., Realdon, O., & Baglio, F. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1154481 · Cited by 39
Differences in brain aging between sexes in Parkinson’s disease
Beheshti, I., Booth, S., & Ko, J. H. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00646-w · Cited by 38
Current treatment of behavioral and cognitive symptoms of Parkinson's disease
Rektorová, I. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.02.042 · Cited by 36
Barbosa, R. P., Mendonça, M., Caetano, A., Lampreia, T., Miguel, R., & Bugalho, P. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02042-8 · Cited by 36
Mahmood, Z., Patten, R. V., Nakhla, M. Z., Twamley, E. W., Filoteo, J. V., & Schiehser, D. M. (2020) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617720000430 · Cited by 36
Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset
Schierding, W. S., Farrow, S. L., Fadason, T., Graham, O. E. E., Pitcher, T. L., Qubisi, S., Davidson, A. J., Perry, J. K., Anderson, T., Kennedy, M. A., et al. (2020) · Movement Disorders · doi:10.1002/mds.28144 · Cited by 37
Association of the serum microRNA-29 family with cognitive impairment in Parkinson's disease
Han, L., Tang, Y., Bai, X., Liang, X., Fan, Y., Shen, Y., Huang, F., & Wang, J. (2020) · Aging · doi:10.18632/aging.103458 · Cited by 36
Pedersen, C. C., Lange, J., Førland, M. G. G., Macleod, A. D., Alves, G. W., & Maple‐Grødem, J. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00196-5 · Cited by 36
Subjective cognitive decline in idiopathic Parkinson´s disease: A systematic review
Oedekoven, C., Egeri, L., Jessen, F., Wagner, M., & Dodel, R. C. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101508 · Cited by 36
Effects of the FNDC5/Irisin on Elderly Dementia and Cognitive Impairment
Peng, J., & Wu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.863901 · Cited by 42
Temporal trajectory of biofluid markers in Parkinson’s disease
Baek, M. S., Lee, M. J., Kim, H., & Lyoo, C. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-94345-8 · Cited by 35
Yu, Y., Lv, J., Liu, J., Chen, Y., Chen, K., & Yang, Y. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03473-x · Cited by 35
Multi-omic integration via similarity network fusion to detect molecular subtypes of ageing
Yang, M., Matan-Lithwick, S., Wang, Y., De Jager, P. L., Bennett, D. A., & Felsky, D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad110 · Cited by 35
New Therapeutic Strategies for Lewy Body Dementias
Velayudhan, L., Ffytche, D. H., Ballard, C. G., & Aarsland, D. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0778-2 · Cited by 37
Self-citationRBD: a red flag for cognitive impairment in Parkinson's disease?
Lin, Y., & Chen, S. (2018) · Sleep Medicine · doi:10.1016/j.sleep.2018.01.006 · Cited by 38
Review: Clinical, neuropathological and genetic features of Lewy body dementias
Hansen, D., Ling, H., Lashley, T., Holton, J. L., & Warner, T. T. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12554 · Cited by 41
Gorges, M., Kunz, M. S., Müller, H., Liepelt‐Scarfone, I., Storch, A., Dodel, R. C., Hilker‐Roggendorf, R., Berg, D., Kalbe, E., Braak, H., et al. (2019) · Human Brain Mapping · doi:10.1002/hbm.24884 · Cited by 35
Hydrogen sulfide enhances adult neurogenesis in a mouse model of Parkinson’s disease
Zhang, L., Qiao, C., Wang, M., Tang, J., Wang, L., & Yu, J. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.301026 · Cited by 37
Metadata
- Authors
- Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C.
- Affiliations
- King's College London (GB)
- Corresponding author
- Aarsland, Dag
- Venue
- Nature Reviews Neurology
- Published
- 2017-03-03
- Volume
- 13
- Issue
- 4
- Pages
- 217-231
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC5643027
- OpenAlex
- W2593272776
- Cited by
- 1,027
- References
- 216
- Citations by year
- 2026: 102 · 2025: 99 · 2024: 138 · 2023: 104 · 2022: 105 · 2021: 171 · 2020: 116 · 2019: 89 · 2018: 68 · 2017: 33
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- South London and Maudsley NHS Foundation Trust
- National Institute for Health and Care Research
- King's College London
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, cognitive decline, Parkinson's disease dementia, mild cognitive impairment, cerebrospinal fluid biomarkers, amyloid-beta 42, Lewy body pathology, APOE ε4, GBA mutations, cognitive training, nootropic drugs
- MeSH terms
- Dementia, Humans, Parkinson Disease, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
